Big Pharma Wants To Turn Toad Venom Into The Next Blockbuster Drug

Jul 27, 2026 · 6:45 PM UTC ·4 min read · 0 reactions · 0 comments · 5 views

TL;DR · WeSearch summary

Pharmaceutical companies are pouring billions into a drug called 5-MeO-DMT, often known as bufo, a powerful psychedelic compound that is naturally found in the poison secreted from the Colorado River toad. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison. Watch more: 🎥 https://t.co/2foNhUN4Ir pic.twitter.com/yinNXgHjyU— The Wall Street Journal (@WSJ) July 25, 2026 Typical anti-depressants already come with a host of serious negative side effects.

Key facts

▪Pharmaceutical companies are pouring billions into a drug called 5-MeO-DMT, often known as bufo, a powerful psychedelic compound that is naturally found in the poison secreted from the Colorado River toad.
▪WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.
▪Watch more: 🎥 https://t.co/2foNhUN4Ir pic.twitter.com/yinNXgHjyU— The Wall Street Journal (@WSJ) July 25, 2026 Typical anti-depressants already come with a host of serious negative side effects.

About this source

The Daily Caller files mainly under politics. We currently carry 798 of its stories.

All The Daily Caller coverage →

Original article

Dailycaller

Read full at Dailycaller →

Story provenance

Source · retrieval · rights · ranking — open for full record

inspect →

Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.

Record

Original publisher	Dailycaller
Canonical URL	https://dailycaller.com/2026/07/27/big-pharma-toad-venom-next-blockbuster-drug-eli-lilly-ataibeckley
Publication time	Mon, 27 Jul 2026 18:45:09 +0000
Retrieval time	2026-07-27T19:16:42.648Z
Last seen	2026-07-27T19:16:42.648Z
Headline source	Publisher (no WeSearch rewrite)
Excerpt source	publisher body
Excerpt method	First ~120 words (~800 chars) of extracted publisher body, fair-use limited.
Summary	WeSearch · cerebras-chat (WeSearch summarizer)
Summary source text	contentText
Citation coverage	Summary is a WeSearch-generated derivative; primary citation is the original publisher URL.
Cluster	A9s34EbW7xeS · 1 stories
Cluster logic	Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison.
Ranking reason	Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking.
Publisher visit	Yes — open original
Substitutes article?	No — link-out required for full text

Rights status (four layers)

Publisher-declared

No publisher-confirmed rights record for this source yet.

Machine-readable

No source-specific machine-readable restriction detected beyond the public feed.

WeSearch interpretation

WeSearch declared handling (basis: Derived from the published RSS/Atom feed). This is WeSearch policy, not a legal grant on the publisher's behalf.

Unknown

Retrieval and training permissions are not asserted unless the publisher confirms them.

WeSearch handling by dimension

Indexing	May the item be indexed (stored, ranked, made findable)?	Allowed
Snippet	May a short excerpt of the publisher's text be shown?	Allowed
AI summary	May WeSearch generate its own short summary of the article?	Limited
Retrieval / RAG	May the content be exposed for third-party retrieval-augmented generation?	Not asserted
Model training	May the content be used to train AI models?	Not asserted
Commercial reuse	May the content be reused commercially?	Not permitted

Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.

Open original publisher → Source rights JSON → Machine-readable provenance → Rights framework → WESEARCH-STORY-PROVENANCE-V1

Opening excerpt (first ~120 words) tap to expand

Health Big Pharma Wants To Turn Toad Venom Into The Next Blockbuster Drug (Photo by RODRIGO BUENDIA/AFP via Getty Images) Ann Rodgers July 27, 2026 2:45 PM ET July 27, 2026 2:45 PM ET Ann Rodgers Font Size: const observer = new MutationObserver((mutations) => { const adDivToHide = document.querySelector("#dailycaller_incontent_1"); if (adDivToHide && dc_noads_page) { adDivToHide.classList.add("hide-premium", "hide-free"); observer.disconnect(); console.log("Ad div found and hidden"); } }); observer.observe(document.body, { childList: true, subtree: true }); Big Pharma is making a high-stakes bet that their next cash grab will come from an unlikely source: the psychedelic venom of toads.

…

Excerpt limited to ~120 words for fair-use compliance. The full article is at Dailycaller.

Anonymous · no account needed

Discussion

0 comments